OOIR: Observatory of International Research

Papers

(The H4-Index of npj Precision Oncology is 48. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
KMT2C inactivation leads to PTEN downregulation and tolerance to DNA damage during cell cycle progression	472
MYSM1 promotes lung adenocarcinoma progression via TRAF2/3-mediated activation of MAPK and non-canonical NF-κB pathways	252
The dynamic immune behavior of primary and metastatic ovarian carcinoma	176
Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study	175
Exosome- transported FER inhibitor suppresses progression of diffuse large B-cell lymphoma via regulating AJUBA/Hippo axis	163
BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study	156
A protein-encoding CCDC7 circular RNA inhibits the progression of prostate cancer by up-regulating FLRT3	150
Artificial intelligence-driven prediction of lymph node metastasis in T1 esophageal squamous cell carcinoma using whole slide images	138
Grading of lung adenocarcinomas with simultaneous segmentation by artificial intelligence (GLASS-AI)	125
Constitutional mismatch repair deficiency mimicking Lynch syndrome is associated with hypomorphic mismatch repair gene variants	109
AI-enabled single-cell dissection of the palmitoylation landscape identifies a multicellular prognostic program in gastric cancer	109
Genome-wide analyses reveals an association between invasive urothelial carcinoma in the Shetland sheepdog and NIPAL1	105
Developing survival prediction models in colorectal cancer using epigenome-wide DNA methylation data from whole blood	103
Author Correction: An automated deep learning pipeline for EMVI classification and response prediction of rectal cancer using baseline MRI: a multi-centre study	89
Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson	79
High-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRASG12D colorectal cancer	78
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada	78
Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs	76
Tumor break load quantitates structural variant-associated genomic instability with biological and clinical relevance across cancers	74
Deciphering brain metastasis in epithelial ovarian cancer: multimodal analysis and potential biomarkers	73
Spatial transcriptomics reveals molecular heterogeneity and subtype-specific therapeutic targets in small cell lung cancer	70
Single nuclei and spatial profiling of sacrococcygeal teratomas reveals cellular composition and X inactivation heterogeneity	69
Interferon signaling and ferroptosis in tumor immunology and therapy	69
Development and testing of a polygenic risk score for breast cancer aggressiveness	69
Sub-regional radiomics combining multichannel 2-dimensional or 3-dimensional deep learning for predicting neoadjuvant chemo-immunotherapy response in esophageal squamous cell carcinoma: a multicenter	67

A multi-center study on the consistency of drug sensitivity testing in patients with acute myeloid leukemia	67
Patient-level proteomic network prediction by explainable artificial intelligence	66
Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials	65
Multi-modal characterization of metabolic and immune gene clusters in adrenocortical carcinoma treatment	65
Robust multicentre detection and classification of colorectal liver metastases on CT: application of foundation models	63
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates	62
Complement activation in tumor microenvironment after neoadjuvant therapy and its impact on pancreatic cancer outcomes	60
Mucin-1: a promising pan-cancer therapeutic target	60
Improved prediction of MAPKi response duration in melanoma patients using genomic data and machine learning	59
An automated deep learning pipeline for EMVI classification and response prediction of rectal cancer using baseline MRI: a multi-centre study	58
Imaging and AI based chromatin biomarkers for diagnosis and therapy evaluation from liquid biopsies	58
Development of a translational murine model for antibody-drug conjugate-induced interstitial lung disease	58
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP	58
Barriers and opportunities in pancreatic cancer immunotherapy	56
User-centered design approach to visualize PROMs for molecular tumor boards	53
Prospective implementation of an aqueous humor liquid biopsy platform informs clinical diagnosis and management of retinoblastoma and other intraocular lesions	53
Enhanced efficacy of ipilimumab plus nivolumab in angiogenic subtypes of metastatic clear-cell renal cell carcinoma	51
Venetoclax resistance in preclinical KMT2A-rearranged acute lymphoblastic leukemia models is characterized by high inter- and intra-model heterogeneity	50
PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells	50
Establishing predictive machine learning models for drug responses in patient derived cell culture	49
Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy	48
Discovery of prognostic lncRNAs in colorectal cancer using spatial transcriptomics	48
Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients	48